Article

Zealand Pharma is leveraging artificial intelligence to enhance drug development for metabolic diseases, including severe obesity, with plans to advance over ten candidates to clinical development within five years. The company, backed by over $2.5 billion in funding, aims to build a highly valuable pipeline and has partnered with Roche and Boehringer Ingelheim on key projects. CEO Adam Steensberg announced these ambitions during the JP Morgan health conference, highlighting access to DCAI's supercomputer Gefion for innovation.